Vaccines have saved millions of lives, but nobody likes getting a shot. That’s why scientists are trying to develop oral vaccines for infectious diseases.
But to be effective, the vaccine must survive digestion and reach immune cells within the intestinal wall. Now, researchers reporting in the ACS journal Nano Letters have developed oral vaccines powered by micromotors that target the mucus layer of the intestine.
In addition to avoiding needles, oral vaccines can generate a broader immune response by stimulating immune cells within the mucus layer of the intestine to produce a special class of antibody called immunoglobulin A (IgA). Joseph Wang, Liangfang Zhang and colleagues wondered if they could use magnesium particles as tiny motors to deliver an oral vaccine against the bacterial pathogen Staphylococcus aureus. When coated over most of their surfaces with titanium dioxide, magnesium microparticles use water as fuel to generate hydrogen bubbles that power their propulsion.
To develop the oral vaccine, the researchers coated magnesium micromotors with red blood cell membranes that displayed the Staphylococcal ?-toxin, along with a layer of chitosan to help them stick to the intestinal mucus. Then, they added an enteric coating that protects drugs from the acidic conditions of the stomach. When given orally to mice, the micromotors safely passed through the stomach, and then the enteric coating dissolved, activating the motors. Imaging of mice that had been given the vaccine showed that the micromotors accumulated in the intestinal wall much better than non-motorized particles. The micromotors also stimulated the production of about ten times more IgA antibodies against the Staphylococcal ?-toxin than the static particles.
Learn more: Micromotors deliver oral vaccines
The Latest on: Oral vaccines
via Google News
The Latest on: Oral vaccines
- Historically Speaking: Exeter’s vaccine pioneerson January 27, 2021 at 1:40 pm
The first people eligible for vaccination in Exeter were first- and second-graders. These kids, born in 1948 and ’49, are now members of the COVID-19 1-B club.
- What to know about allergic reactions to the vaccineson January 27, 2021 at 8:50 am
Recently a batch of coronavirus vaccine was held and reviewed by health officials because several people had reactions. State epidemiologist Dr. Erica Pan said last Wednesday that the review found “no ...
- Vaxart Announces Publication of a Peer-reviewed Journal Article Showing the Potential Clinical and Economic Value of a Norovirus Vaccineon January 27, 2021 at 5:30 am
Vaxart, Inc.,, a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, including a Phase 2 ready norovirus program, announced today ...
- Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publicationon January 26, 2021 at 11:57 pm
New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models An article published in Nature Medicine reports data from a collaboration with ...
- Discover Oral Rotavirus Vaccine Market to grow at a much faster rate beyond 2020| Financial Analysis and Forecaston January 26, 2021 at 10:48 pm
Market.Biz –:Oral Rotavirus Vaccine Businesses must navigate the financial and operational challenges of coronavirus while rapidly addressing the needs of their people, customers, and suppliers.
- What a COVID Vaccine Means for People With Psoriasison January 25, 2021 at 2:26 pm
Is the COVID vaccine safe if you have psoriasis? The experts say yes, even if you're taking a biologic. Here's what you need to know before getting a shot.
- Merck drops 2 potential COVID-19 vaccines after poor results in early testingon January 25, 2021 at 10:00 am
Merck is pulling the plugs on two potential COVID-19 vaccines following poor results in early-stage studies. The drugmaker said Monday it will focus instead on studying two possible treatments for the ...
- Merck ends COVID-19 vaccine program, cites inferior immune responseson January 25, 2021 at 3:59 am
Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral ...
- Cholera Vaccines Oral Live Market 2021 by Growing Demands, Sales, Revenue, Gross Margin, Geographical Regions, and Forecast to 2027on January 25, 2021 at 12:11 am
Jan (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Cholera Vaccines Oral Live Market” ...
- Key Capital COVID-19 Oral Pill Vaccine Records 90% Reduction in Virus Infectivity in Early Studyon January 18, 2021 at 2:20 pm
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine. NEW YORK, NY / ACCESSWIRE / January 18, 2021 / KEY ...
via Bing News